Table 3– Serum creatinine concentrations ([creat]) in lung cancer patients receiving 1–4 cycles of high-dose cisplatin (Cp) chemotherapy for lung cancer

Cp cycle	NC	CD	DMIH
1st
Patients	80	110	52
[creat] μmol·L⁻¹
Pre-Cp	77±1	78±1^#	77±3^#
Post-Cp	82±2^*	95±4^*,¶	94±4^*,¶
2nd
Patients	68	96	49
[creat] μmol·L⁻¹
Pre-Cp	80±2	86±2^#	82±3^#
Post-Cp	88±4^*	105±5^*¶	110±6^*,¶
3rd
Patients	42	64	31
[creat] μmol·L⁻¹
Pre-Cp	85±3	91±3^#	83±4^#
Post-Cp	91±5^*	113±5^*,¶	117±9*^,¶
4th
Patients	35	47	30
[creat] μmol·L⁻¹
Pre-Cp	84±4	95±3^ns	89±3^#
Post-Cp	93±5^*	117±8^*#	121±5*^,¶

Data are presented as n or mean±sem. NC: no comorbidity; CD: hypertension and ischaemic heart disease; DMIH: diabetes mellitus and ischaemic heart disease. *: p<0.05 compared with pre-Cp (paired t-test); ^#: not significant compared with NC (two-way ANOVA with Bonferroni after test); ^¶: p<0.05 compared with NC (two-way ANOVA with Bonferroni after test).